Right to Try laws allow Big Pharma to exploit patients' hope

“Right to Try laws allow Big Pharma to exploit patients’ hope,” Diana Zuckerman, Chicago Tribune.

If you were dying of a terminal illness and your doctor said there were no proven treatments, would you take the risk of trying an experimental, unproven drug? Many patients would say yes. But as with most medical decisions, the . . . → Read More: Right to Try laws allow Big Pharma to exploit patients’ hope

Trumping the Affordable Care Act

“On day one of the Trump Administration, we will ask Congress to immediately deliver a full repeal of Obamacare.

However, it is not enough to simply repeal this terrible legislation. We will work with Congress to make sure we have a series of reforms ready for implementation that follow free market . . . → Read More: Trumping the Affordable Care Act

Congress Shouldn’t Pass FDA Reform Bills Without Addressing Patient Safety and Drug Prices

“Congress Shouldn’t Pass FDA Reform Bills Without Addressing Patient Safety and Drug Prices,” Diana Zuckerman, The Health Care Blog.

A major proposed law that alters the way the Food and Drug Administration (FDA) approves drugs and medical devices has been wending its way through Congress since 2014. The Cures bill and Senate legislation seek . . . → Read More: Congress Shouldn’t Pass FDA Reform Bills Without Addressing Patient Safety and Drug Prices

The Lown Institute's RightCare Alliance

The Lown Institute’s RightCare Alliance is a grassroots movement of clinicians, patients, and community leaders who are demanding and creating change to the healthcare industry — one that sees patients as people, not profits, and gives everyone access not just to care but to the RIGHT CARE for their medical needs.

Learn more: www.rightcarealliance.org . . . → Read More: The Lown Institute’s RightCare Alliance

How Doctors Take Women's Pain Less Seriously

“How Doctors Take Women’s Pain Less Seriously,” The Atlantic, Oct. 15, 2015.

When my wife was struck by mysterious, debilitating symptoms, our trip to the ER revealed the sexism inherent in emergency treatment.

“Female pain might be perceived as constructed or exaggerated”: We saw this from the moment we entered the hospital, as the staff . . . → Read More: How Doctors Take Women’s Pain Less Seriously

The 21st Century Cures Act

In May 2015, the “21st Century Cures Act” was introduced in the U.S. House of Representatives with the goal of promoting the development and speeding the approval of new drugs and devices. Championed by the pharmaceutical, biotechnology, and device industries, some of its provisions could have a significant impact on clinical trial design, what is . . . → Read More: The 21st Century Cures Act

Breast Cancer Screening, Incidence, and Mortality Across U.S. Counties

A study published (July 6, 2015) in JAMA Internal Medicine finds that more widespread breast cancer screening does not save lives as once believed. It does, however, lead to widespread over-diagnosis, as it detects cancers that would not have been fatal or harmful.

This ecological study (comparing groups, rather than individuals) covered the . . . → Read More: Breast Cancer Screening, Incidence, and Mortality Across US Counties

How Not to Fix the F.D.A.

“How Not to Fix the F.D.A.,” by The Editorial Board, The New York Times.

A bill passed by the House and ostensibly designed to streamline the Food and Drug Administration is loaded with bad provisions and may not even be necessary. The Senate should either eliminate or rewrite the flawed . . . → Read More: How Not to Fix the F.D.A.

Early-stage breast cancer patients get too much testing: study

“Early-stage breast cancer patients get too much testing: study,” by Elizabeth Payne, Ottawa Citizen.

A study of 26,547 patients found that nearly 80 per cent of those with Stage 1 breast cancer and more than 90 per cent of those with Stage 2 had unnecessary tests, according to guidelines set out by Cancer Care Ontario, . . . → Read More: Early-stage breast cancer patients get too much testing: study

Murky Devices: The PIP Breast Implant Scandal

In March 2010, French company Poly Implant Prothèse (PIP), a manufacturer of silicone breast implants since 1991 and one of the main producers of silicone breast implants for Europe and Latin America, was implicated in a scandal over a high rate of implant ruptures and use of substandard silicone. PIP had been using industrial-grade silicone . . . → Read More: Murky Devices: The PIP Breast Implant Scandal

Articles & Posts